Shopping Cart
Remove All
Your shopping cart is currently empty
SCL-1
😃Good
Catalog No. T212428Cas No. 1061105-16-5
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor that disrupts the interaction between PD-1 and PD-L1. It enhances the numbers of T cells, B cells, and natural killer cells. SCL-1 exhibits potent tumor growth inhibitory effects by inducing effector T cells within the tumor and upregulating the expression of long non-coding RNAs as neoantigens, thereby activating cytotoxic T lymphocytes. SCL-1 is applicable in cancer research, including studies on triple-negative breast cancer.
SCL-1
😃Good
Catalog No. T212428Cas No. 1061105-16-5
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor that disrupts the interaction between PD-1 and PD-L1. It enhances the numbers of T cells, B cells, and natural killer cells. SCL-1 exhibits potent tumor growth inhibitory effects by inducing effector T cells within the tumor and upregulating the expression of long non-coding RNAs as neoantigens, thereby activating cytotoxic T lymphocytes. SCL-1 is applicable in cancer research, including studies on triple-negative breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor that disrupts the interaction between PD-1 and PD-L1. It enhances the numbers of T cells, B cells, and natural killer cells. SCL-1 exhibits potent tumor growth inhibitory effects by inducing effector T cells within the tumor and upregulating the expression of long non-coding RNAs as neoantigens, thereby activating cytotoxic T lymphocytes. SCL-1 is applicable in cancer research, including studies on triple-negative breast cancer. |
| In vitro | SCL-1 (0.25-100 μM, 4 days) does not exhibit significant cytotoxicity to MDA-MB231 cells. At a concentration of 25 μM, SCL-1 shows moderate inhibitory activity for PD-1/PD-L1 binding, with an inhibition rate of 63%. Additionally, SCL-1 inhibits the proliferation of SCC3 and Jurkat cells, with IC 50 values both greater than 50 μM. |
| In vivo | SCL-1, administered orally at doses of 25-100 mg/kg, ten times over 14 days, inhibits tumor growth in MHC-dKO NOG mice with humanized MDA-MB231 tumor load. Similarly, SCL-1 at a dose of 50 mg/kg, given orally under the same schedule, reduces tumor growth in MHC-dKO NOG mice with humanized SCC-3 tumor load. |
| Molecular Weight | 396.41 |
| Formula | C18H23F3N6O |
| Cas No. | 1061105-16-5 |
| Smiles | O=C(N1CCCCC1C)C2CCN(C3=NN4C(=NN=C4C(F)(F)F)C=C3)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy SCL-1 | purchase SCL-1 | SCL-1 cost | order SCL-1 | SCL-1 chemical structure | SCL-1 in vivo | SCL-1 in vitro | SCL-1 formula | SCL-1 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.